Bausch Health Companies (BHC.TO, BHC), down near 1% at last look, on Friday said the Centers for Medicare and Medicaid Services (CMS) has selected Xifaxan (rifaximin) 550 mg tablets for the second round of negotiation as part of the Inflation Reduction Act.
"We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that Xifaxan delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave Xifaxan the highest possible recommendation (Grade I, A,1) via their practice guidelines," Bausch said in a statement.
Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
The company's stock was last seen down $0.13 to $10.88, on the Toronto Stock Exchange.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。